Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Martin Moore | M | - |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | 10 jaar |
Alexandre Le Vert | M | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | 7 jaar |
Roderick Tang | M | - |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | 10 jaar |
Catharina Boehme | F | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | 19 jaar |
Fergal Hill | M | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | 7 jaar |
Florence Nicolas | M | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | 7 jaar |
Thomas Joudinaud | M | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | - |
Janelle Muranaka | F | - |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | - |
Hugues Wallemacq | M | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | - |
Frank Glavin | M | - |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | 2 jaar |
Christian Frutiger | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Sergio Carmona | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Ilona Kickbusch | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Andrew Jack | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Sheila Dinotshe Tlou | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
David L. Heymann | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
George F. Gao | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Mark Kessel | M | 82 |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Kenneth Kelley | M | 64 |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | 5 jaar |
Maunatlala Mehlape | M | 58 |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | 20 jaar |
Tyrell J. Rivers | M | 51 |
VaxEquity Ltd.
VaxEquity Ltd. BiotechnologyHealth Technology VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. | - |
Alexandre Heraud | M | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | 6 jaar |
Marcel Tanner | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Carlos Morel | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Christian Pradeyrol | M | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | - |
Isaac Cheng | M | 49 |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | - |
William F. Daly | M | - |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | 5 jaar |
Christopher Martin | M | 65 |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | 1 jaar |
Stephanie O'Brien | F | 65 |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | - |
Shobana Kamineni | F | 63 |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Daniel Camus | M | 70 |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | - |
Soumya Swaminathan | M | - |
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Zwitserland | 15 | 46.88% |
Frankrijk | 8 | 25.00% |
Verenigde Staten | 8 | 25.00% |
Verenigd Koninkrijk | 1 | 3.13% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Michael Watson
- Persoonlijk netwerk